.Merck & Co.'s TIGIT plan has actually suffered another obstacle. Months after shuttering a stage...
.After a year described by pipe cuts, the shift of its own CEO as well as layoffs, Exscientia will c...
.Cullinan Rehab was actually excited good enough with Harbour BioMed's bispecific immune activator t...
.Within this full week's incident of "The Top Pipe," we are actually diving right into Brutal Biotec...
.The confetti is still flying from Eli Lilly's gathering celebrating the approval of Alzheimer's ail...
.Welcome to recently's Chutes & Ladders, our roundup of significant management hirings, firings a...
.Following an inadequate revealing for Lykos Therapeutics' MDMA prospect for post-traumatic stress d...
.AN2 Therapeutics is re-thinking its service in response to poor midphase data, vowing to give up ha...
.Merck & Co. is paying out $700 million beforehand to test Amgen in a blood cancer market. The of...
.Along With Gilead Sciences about to an FDA decision for its liver ailment drug seladelpar, the busi...